TGFBI and cancer: In thirty-three TCGA transcriptomic cohorts, TGFBI was a poor indicator of seven cancer types, including head and neck cancer; HYAL1 was a protective marker for four cancer types, including kidney renal clear cell carcinoma and uveal melanoma.